US institution changes share price target for three big Danish drugmakers

Three of Denmark’s biggest life science firms, Novo Nordisk, Lundbeck and Genmab, have had their share price target adjusted by a private wealth manager in the US.
Photo: Jens Dresling
Photo: Jens Dresling
by marketwire, translated by daniel pedersen

US-based private wealth manager Bernstein has taken stock of three large Danish drugmakers – Novo Nordisk, Lundbeck and Genmab – resulting in share price target changes for all three, Bloomberg News reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading